Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Ofatumumab is a high-efficacy, first-line disease-modifying therapy (DMT) with a favourable benefit-risk profile recently approved in Canada to treat relapsing-remitting Multiple Sclerosis (RRMS) with active disease. This research evaluates the cost effectiveness of ofatumumab against other DMTs and best supportive care (BSC) for the treatment of adult patients with RRMS from a Canadian healthcare system perspective.